Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sareum Holdings ( (GB:SAR) ) has provided an announcement.
Sareum Holdings has acquired the licence for SRA737, a clinical-stage oral Checkpoint kinase 1 inhibitor targeting cancer cell replication and DNA damage repair. This acquisition follows the programme’s return from a US-based biopharma company, with Sareum now securing a 63.5% share of future revenues. The move strengthens Sareum’s position to explore partnerships or development opportunities for SRA737, while ongoing costs will be limited to material and data storage, and intellectual property management. Sareum is also advancing its lead programme, SDC-1801, which has shown promising results in treating autoimmune diseases.
More about Sareum Holdings
Sareum Holdings PLC is a clinical-stage biotechnology company based in Cambridge, UK, focused on developing next-generation kinase inhibitors for autoimmune diseases and cancer.
YTD Price Performance: -32.65%
Average Trading Volume: 180,726
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £20.61M
Learn more about SAR stock on TipRanks’ Stock Analysis page.